Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos
- PMID: 9171368
- DOI: 10.1101/gad.11.10.1226
Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos
Abstract
Mutations of the human BRCA1 and BRCA2 genes encoding tumor suppressors have been implicated in inherited predisposition to breast and other cancers. Disruption of the homologous mouse genes Brca1 and Brca2 by targeting showed that they both have indispensable roles during embryogenesis, because nullizygous embryos become developmentally retarded and disorganized, and die early in development. In Brca1 mutants, the onset of abnormalities is earlier by one day and their phenotypic features and time of death are highly variable, whereas the phenotype of Brca2 null embryos is more uniform, and they all survive for at least 8.5 embryonic days. Observations with Brca1/Brca2 double nullizygotes raise the possibility that the two developmental pathways could be linked. Interestingly, the impact of the Brca1 or Brca2 null mutation is less severe in a p53 null background.
Similar articles
-
Brca2 is required for embryonic cellular proliferation in the mouse.Genes Dev. 1997 May 15;11(10):1242-52. doi: 10.1101/gad.11.10.1242. Genes Dev. 1997. PMID: 9171369
-
BRCA2-null embryonic survival is prolonged on the BALB/c genetic background.Mol Carcinog. 2000 Jul;28(3):174-83. doi: 10.1002/1098-2744(200007)28:3<174::aid-mc6>3.0.co;2-c. Mol Carcinog. 2000. PMID: 10942534
-
Developmental studies of Brca1 and Brca2 knock-out mice.J Mammary Gland Biol Neoplasia. 1998 Oct;3(4):431-45. doi: 10.1023/a:1018792200700. J Mammary Gland Biol Neoplasia. 1998. PMID: 10819537 Review.
-
Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium.Lancet. 1997 May 24;349(9064):1505-10. Lancet. 1997. PMID: 9167459
-
BRCA1 and BRCA2 and the genetics of breast and ovarian cancer.Hum Mol Genet. 2001 Apr;10(7):705-13. doi: 10.1093/hmg/10.7.705. Hum Mol Genet. 2001. PMID: 11257103 Review.
Cited by
-
Interactions between human BRCA2 protein and the meiosis-specific recombinase DMC1.EMBO J. 2007 Jun 20;26(12):2915-22. doi: 10.1038/sj.emboj.7601739. Epub 2007 May 31. EMBO J. 2007. PMID: 17541404 Free PMC article.
-
A selective requirement for 53BP1 in the biological response to genomic instability induced by Brca1 deficiency.Mol Cell. 2009 Aug 28;35(4):534-41. doi: 10.1016/j.molcel.2009.06.037. Mol Cell. 2009. PMID: 19716796 Free PMC article.
-
Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers.BMC Cancer. 2006 Mar 24;6:80. doi: 10.1186/1471-2407-6-80. BMC Cancer. 2006. PMID: 16563154 Free PMC article.
-
The CIP2A-TOPBP1 axis safeguards chromosome stability and is a synthetic lethal target for BRCA-mutated cancer.Nat Cancer. 2021 Dec;2(12):1357-1371. doi: 10.1038/s43018-021-00266-w. Epub 2021 Nov 11. Nat Cancer. 2021. PMID: 35121901
-
The dependence of the risk of breast cancer in women on their genotype.Dokl Biol Sci. 2004 Sep-Oct;398:391-4. doi: 10.1023/b:dobs.0000046665.26444.e7. Dokl Biol Sci. 2004. PMID: 15587796 No abstract available.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous